Savara Inc - Company Profile
Powered by 
All the sales intelligence you need on Savara Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Savara Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Savara Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Savara Inc (Savara) is a clinical-stage biopharmaceutical company primarily engaged in the development of treatments for rare respiratory diseases.The company's main product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase III development. This product is designed to treat autoimmune pulmonary alveolar proteinosis (aPAP), a rare respiratory condition. Molgramostim is delivered via a proprietary eFlow Nebulizer System, a brand associated with PARI Pharma GmbH. The product is intended for patients suffering from rare respiratory diseases, specifically those with aPAP. The company operates in the biopharmaceutical industry, focusing on the development of treatments for rare respiratory diseases. Savara is headquartered in Langhorne, Pennsylvania, the US.
Headquarters
United States of America
Address
1717 Langhorne Newtown Road, Suite 300, Pennsylvania, 19047
Website
savarapharma.com
Telephone
1 512 6141848
No of Employees
70
Industry
Medical Equipment
Ticker Symbol & Exchange
SVRA (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-23.9%
(2024 vs 2023)
Market Cap*
$1.1B
Net Profit Margin (0 vs)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Savara Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline - | Molgradex |
| MOLBREEVI |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | New Products/Services | In September, the company announced the Savara early access program, a molgramostim expanded access program (EAP) for patients with autoimmune pulmonary alveolar proteinosis (aPAP). |
| 2023 | New Products/Services | In December, the company launched aPAP ClearPath, a new serum-based blood test. |
| 2019 | Regulatory Approval | In December, the company received Breakthrough Therapy designation approval for US FDA for Molgradex. |
Competitor Comparison
| Key Parameters | Savara Inc | Gilead Sciences Inc | Vertex Pharmaceuticals Inc | TFF Pharmaceuticals Inc | AbVacc Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Langhorne | Foster City | Boston | Austin | Rockville |
| State/Province | Pennsylvania | California | Massachusetts | Texas | Maryland |
| No. of Employees | 70 | 17,000 | 6,400 | 19 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Matthew Pauls | Chief Executive Officer; Chairman | Executive Board | 2020 | 54 |
| Robert Lutz | Chief Operating Officer; Chief Financial Officer | Senior Management | 2026 | 56 |
| Kate McCabe | Chief Legal Officer | Senior Management | 2024 | 39 |
| Yasmine Wasfi | Chief Medical Officer | Senior Management | 2025 | - |
| Anne Erickson | Chief Business Officer | Senior Management | 2023 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer